What were the main drivers of Edwards Lifesciences' sales growth in 2019?

The primary driver of sales growth in 2019 was the strong performance of Transcatheter Aortic Valve Replacement (TAVR) products, particularly the Edwards SAPIEN 3 and SAPIEN 3 Ultra systems, which saw increased adoption, especially in the United States. Growth in Surgical Structural Heart and Critical Care segments also contributed positively.

How did the company manage its intellectual property litigation expenses?

Edwards Lifesciences incurred intellectual property litigation expenses, including a significant settlement of $180 million with Boston Scientific in January 2019 to resolve all outstanding patent disputes.

What is the company's strategy regarding product development and innovation?

Edwards Lifesciences is heavily invested in research and development, dedicating 17.3% of its net sales in 2019 to innovation. Key focus areas include advancing transcatheter therapies for mitral and tricuspid valve diseases, developing new TAVR technologies, and enhancing its critical care monitoring systems.

What is the company's financial health and outlook based on this report?

The company demonstrated strong revenue growth and healthy profitability in 2019. With a solid balance sheet, ongoing investment in R&D, and a leading position in key medical device markets, Edwards Lifesciences appears well-positioned for continued growth, though it faces ongoing competition and regulatory considerations.

EW 10-K FY2019 Annual Report — Revenue, Net Income, EPS

Summary

Edwards Lifesciences Corporation (EW) reported robust growth in its 2019 fiscal year, driven primarily by its Transcatheter Aortic Valve Replacement (TAVR) segment, which saw a significant increase in sales due to strong adoption of its SAPIEN 3 and SAPIEN 3 Ultra systems, particularly in the United States. The company's strategic focus on minimally invasive structural heart disease treatments continues to yield positive financial results, with total net sales increasing by 16.8% year-over-year. Investments in research and development also increased, reflecting a commitment to innovation in structural heart disease and critical care monitoring. Despite overall strong performance, the company incurred a $73.1 million charge related to inventory write-offs, including the discontinuation of its CENTERA program, and faced intellectual property litigation expenses. The company remains a leader in its key product areas, including TAVR, Surgical Structural Heart, and Critical Care, with ongoing development of next-generation technologies and expansion into new markets. Looking ahead, Edwards Lifesciences is well-positioned to capitalize on the growing demand for its advanced cardiovascular solutions.

Financial Highlights

55 data points

Beta

Revenue

$4.35B

0.7% Gross Margin

Net Income

$1.05B

0.2% Net Margin

EPS (Diluted)

$1.64

Total Assets

$6.49B

Cash & Equivalents

$1.18B

Free Cash Flow

$928.50M

Financial Statements

Beta

Revenue	$4.35B
Cost of Revenue	$1.11B
Gross Profit	$3.23B
R&D Expenses	$752.70M
SG&A Expenses	$1.24B
Operating Income	$1.15B
Interest Expense	$20.70M
Net Income	$1.05B
EPS (Basic)	$1.68
EPS (Diluted)	$1.64
Shares Outstanding (Basic)	624.80M
Shares Outstanding (Diluted)	636.70M

Key Highlights

1Net sales increased by 16.8% to $4.35 billion in 2019, driven by strong TAVR product performance.
2Transcatheter Aortic Valve Replacement (TAVR) sales grew by 19.9% to $2.74 billion, fueled by the SAPIEN 3 and SAPIEN 3 Ultra systems.
3Surgical Structural Heart sales increased by 10.5% to $841.7 million, supported by the INSPIRIS RESILIA aortic valve.
4Critical Care sales rose by 9.7% to $740.2 million, boosted by the HemoSphere monitoring platform and CASMED acquisition.
5The company invested 17.3% of net sales in research and development, totaling $752.7 million, to drive future innovation.
6Edwards Lifesciences settled patent disputes with Boston Scientific for $180 million in January 2019.
7The company completed the acquisition of CAS Medical Systems, Inc. (CASMED) for $100.8 million to enhance its critical care offerings.

Edwards Lifesciences Corp Annual Report, Year Ended Dec 31, 2019

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions